TY  - JOUR
AU  - Arkenau, Hendrik-Tobias
AU  - Taylor, Donatienne
AU  - Xu, Xiaoying
AU  - Chitnis, Shripad
AU  - Llacer-Perez, Casilda
AU  - Moore, Kathleen
AU  - Nidamarthy, Prasanna Kumar
AU  - Ilankumaran, Palanichamy
AU  - De Vos-Geelen, Judith
PY  - 2022
DO  - 10.1002/cpdd.1052
UR  - http://hdl.handle.net/10668/21730
T2  - Clinical pharmacology in drug development
AB  - This phase 1 postapproval study assessed the effect of the mitogen-activated protein kinase kinase enzyme 1/enzyme 2 inhibitor trametinib (2 mg once daily, repeat dosing) on the pharmacokinetics of combined oral contraceptives (COCs) containing...
LA  - en
KW  - MEK inhibitor
KW  - anaplastic thyroid cancer
KW  - melanoma
KW  - non-small-cell lung cancer
KW  - oral contraception
KW  - trametinib
KW  - Contraceptives, Oral, Combined
KW  - Ethinyl Estradiol
KW  - Female
KW  - Humans
KW  - Male
KW  - Neoplasms
KW  - Norethindrone
KW  - Pyridones
KW  - Pyrimidinones
TI  - Pharmacokinetic Interaction Between the MEK1/MEK2 Inhibitor Trametinib and Oral Contraceptives Containing Norethindrone and Ethinyl Estradiol in Female Patients With Solid Tumors.
TY  - research article
VL  - 11
ER  -